Treat cancers by targeting survivin

Just a dream or future reality?

Mohane Selvaraj Coumar, Fang Ying Tsai, Jagat Rakesh Kanwar, Sailu Sarvagalla, Chun-Hei Cheung

Research output: Contribution to journalReview article

96 Citations (Scopus)

Abstract

Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.

Original languageEnglish
Pages (from-to)802-811
Number of pages10
JournalCancer Treatment Reviews
Volume39
Issue number7
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Neoplasms
Apoptosis
Therapeutics
Autophagy
Mitosis
DNA Repair
Direction compound
Inhibition (Psychology)

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Coumar, Mohane Selvaraj ; Tsai, Fang Ying ; Kanwar, Jagat Rakesh ; Sarvagalla, Sailu ; Cheung, Chun-Hei. / Treat cancers by targeting survivin : Just a dream or future reality?. In: Cancer Treatment Reviews. 2013 ; Vol. 39, No. 7. pp. 802-811.
@article{6b58c41b934f4999a035f90957c55c5b,
title = "Treat cancers by targeting survivin: Just a dream or future reality?",
abstract = "Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.",
author = "Coumar, {Mohane Selvaraj} and Tsai, {Fang Ying} and Kanwar, {Jagat Rakesh} and Sailu Sarvagalla and Chun-Hei Cheung",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.ctrv.2013.02.002",
language = "English",
volume = "39",
pages = "802--811",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "7",

}

Treat cancers by targeting survivin : Just a dream or future reality? / Coumar, Mohane Selvaraj; Tsai, Fang Ying; Kanwar, Jagat Rakesh; Sarvagalla, Sailu; Cheung, Chun-Hei.

In: Cancer Treatment Reviews, Vol. 39, No. 7, 01.11.2013, p. 802-811.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treat cancers by targeting survivin

T2 - Just a dream or future reality?

AU - Coumar, Mohane Selvaraj

AU - Tsai, Fang Ying

AU - Kanwar, Jagat Rakesh

AU - Sarvagalla, Sailu

AU - Cheung, Chun-Hei

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.

AB - Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.

UR - http://www.scopus.com/inward/record.url?scp=84881547700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881547700&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2013.02.002

DO - 10.1016/j.ctrv.2013.02.002

M3 - Review article

VL - 39

SP - 802

EP - 811

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 7

ER -